Nobesine , Propion, Ten-Tab, Tenuate, Tenuate Dospan, Tepanil
Classifications: gastrointestinal agent; anorexiant
Pregnancy Category: B
Controlled Substance: Schedule IV
25 mg tablets; 75 mg sustained release tablets
Sympathomimetic amine and amphetamine congener. Has lower incidence of amphetamine-type adverse effects but reportedly is
less effective as an appetite suppressant. Anorexigenic action probably secondary to direct (CNS) stimulation of appetite
control center in hypothalamus and limbic regions. Also produces mild psychic stimulation and vasopressor effects.
Suppresses appetite as a result of drug action on CNS appetite control center.
Used solely in management of exogenous obesity as short-term (a few weeks) adjunct in a regimen of weight reduction based
on caloric restriction.
Known hypersensitivity or idiosyncrasy to sympathomimetic amines; severe hypertension, advanced arteriosclerosis; hyperthyroidism;
glaucoma; agitated states, history of drug abuse. Safe use during pregnancy (category B) or in children <12 y is not established.
Hypertension, arrhythmias, symptomatic cardiovascular disease; epilepsy; diabetes mellitus; lactation.
Adult: PO 25 mg t.i.d. 3060 min a.c. or 75 mg sustained release q.d. midmorning
Body as a Whole: Hypersensitivity (urticaria, rash, erythema); muscle pain, dyspnea, hair loss, blurred vision, severe dermatoses (chronic
intoxication), increased sweating. CNS: Mild euphoria, restlessness, nervousness, dizziness, headache, irritability, hyperactivity, insomnia, drowsiness, mood changes, lethargy, increase in convulsive episodes
in patients with epilepsy. CV: Palpitation, tachycardia, precordial pain, rise in BP. GI: Nausea, vomiting, diarrhea, constipation, dry mouth, unpleasant taste. Urogenital: Impotence, changes in libido, gynecomastia, menstrual irregularities; polyuria, dysuria.
Drug: Acetazolamide, sodium bicarbonate decrease diethylpropion elimination; ammonium chloride, ascorbic acid increase diethylpropion elimination; a barbiturate and diethylpropion taken together may antagonize the effects of both drugs; furazolidone may increase blood pressure effects of amphetamines, and interaction may persist for several weeks after discontinuation of furazolidone; guanethidine, guanadryl antagonize antihypertensive effects; mao inhibitors, selegiline can cause hypertensive crisis (fatalities reported)amphetamines should not be administered at the same time as or within 14 days of these drugs; phenothiazines may inhibit mood elevating effects of amphetamines; tricyclic antidepressants enhance amphetamines' effects by increasing norepinephrine release; beta agonists increase cardiovascular adverse effects.
Absorption: Readily absorbed from GI tract. Duration: 4 h, regular tablets; 1014 h, sustained release. Elimination: Excreted in urine. Half-Life: 46 h.
- Give on an empty stomach, ½1 h before meals.
- Note: Additional dose sometimes prescribed in midevening to control nighttime hunger. Rarely causes insomnia except in high doses.
- Titrate dosage carefully in patients with diabetes.
- Store between 15°30° C (59°86° F) in well-closed container unless otherwise specified.
Assessment & Drug Effects
- Observe patients with epilepsy closely for reduction in seizure control.
- Anorexigenic effect seldom lasts more than a few weeks. Discontinue if tolerance develops.
- Note: Varying degrees of psychologic and rarely physical dependence can occur.
Patient & Family Education
- Swallow sustained release tablets whole; do NOT chew.
- Do not drive or engage in other potentially hazardous activities until reaction to drug is known.
- Do not breast feed while taking this drug without consulting physician.